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Abstract Endostatin is a fragment of collagen XVIII that acts
as an endogenous inhibitor of tumor angiogenesis and tumor
growth. Anti-tumor e¡ects have been described using both solu-
ble and insoluble recombinant endostatin. However, di¡erences
in endostatin structure are likely to cause di¡erences in bioac-
tivity. In the present study we have investigated the structure
and cellular e¡ects of insoluble endostatin. We found that in-
soluble endostatin shows all the hallmarks of amyloid aggre-
gates. Firstly, it binds Congo red and shows the characteristic
apple-green birefringe when examined under polarized light.
Secondly, electron microscopy shows that endostatin forms
short unbranched ¢brils. Thirdly, X-ray analysis shows the
abundant presence of cross-L sheets, the tertiary structure that
underlies ¢brillogenesis. None of these properties was observed
when examining soluble endostatin. Soluble endostatin can be
triggered to form cross-L sheets following denaturation, indicat-
ing that endostatin is a protein fragment with an inherent pro-
pensity to form amyloid deposits. Like L-amyloid, found in the
brains of patients with Alzheimer’s disease, amyloid endostatin
binds to and is toxic to neuronal cells, whereas soluble endo-
statin has no e¡ect on cell viability. Our results demonstrate a
previously unrecognized functional di¡erence between soluble
and insoluble endostatin, only the latter acting as a cytotoxic
amyloid substance.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years cancer therapy has seen the development of
a new class of drugs: inhibitors of the formation of new blood
vessels (‘angiogenesis’) which thereby limit blood supply to
tumors. A number of anti-angiogenic compounds have proven
to be e¡ective in eradicating tumors in mouse models and are
now being further tested in clinical trials (reviewed in [1^4]).
Endostatin, a naturally occurring fragment of collagen XVIII,
is considered to be one of the most e¡ective inhibitors of
angiogenesis [3]. Early studies with bacterially produced (in-
soluble) endostatin have shown its potent inhibitory e¡ect on
tumor growth [5,6]. Although soluble endostatin (produced in
yeast) can also inhibit tumor growth, permanent tumor re-
gression has only been reported when using insoluble endo-
statin [3]. E¡ects of endostatin on endothelial cell prolifera-
tion [5], apoptosis [7^9] and migration [10,11] have been
described, but it is not clear to what extent these activities
contribute to the anti-angiogenic and anti-tumor e¡ects of
endostatin in vivo. Moreover, it remains unclear why endo-
statin therapy works so well in some experiments [3] but re-
mains ine¡ective in others [12^15] (and our own unpublished
data). Di¡erent structural forms of endostatin are likely to
have distinct bioactivities. Soluble and insoluble endostatin
may therefore produce their anti-angiogenic e¡ects through
distinct mechanisms. In the present report we set out to in-
vestigate the structural and biological di¡erences between
soluble and insoluble endostatin. Whereas the structure of
soluble, globular endostatin has been elucidated [16,17], the
structure of insoluble endostatin has not. Insoluble proteins
may occur as amorphous aggregates but they may also occur
as highly ordered ‘amyloid’ deposits [18]. In the latter case,
the polypeptide backbones are in a L-sheet conformation and
are stacked through intermolecular (rather than intramolecu-
lar) hydrogen bonds, thus forming a ‘cross-L sheet’ [19]. We
found that endostatin is a protein with high propensity to
form amyloid ¢bers through extensive cross-L sheet forma-
tion. Fibrillar endostatin binds to neuronal cells and causes
neuronal cell death, whereas soluble endostatin does not. Our
results suggest that endostatin induces apoptosis as a result of
its amyloid structure.
2. Materials and methods
2.1. Preparation of recombinant human endostatin from bacteria
Endostatin was puri¢ed from bacteria essentially as described in [6].
In short, Bl21.DE3 bacteria expressing endostatin were lysed in a
bu¡er containing 8 M urea, 10 mM Tris (pH 8.0), 10 mM imidazole
and 10 mM L-mercaptoethanol. Folllowing puri¢cation over Ni-aga-
rose, the protein sample was extensively dialyzed against H2O. During
dialysis endostatin precipitates as a ¢ne white solid. Aliquots of this
material were either stored at 380‡C for later use, or were freeze-dried
prior to storage.
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2.2. Recombinant human endostatin from yeast
Endostatin produced by the yeast strain Pichia pastoris was kindly
provided by Dr. Kim Lee Sim (EntreMed, Rockville, MA, USA).
2.3. Preparation of aggregated yeast-produced endostatin
Soluble yeast endostatin was dialyzed overnight in 8 M urea and
subsequently three times against H2O. Like bacterial endostatin, yeast
endostatin precipitates as a ¢ne white solid.
2.4. Amyloid L (AL) and human islet amyloid polypeptide (hIAPP)
AL140 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL-
MVGGVV) and hIAPP (KCNTATCATQRLANFLVHSSNNFGA-
ILSSTNVGSNTY) were obtained from the peptide synthesis facility
at the Netherlands Cancer Insitute (Amsterdam, The Netherlands).
The freeze-dried peptides were resuspended in phosphate-bu¡ered sa-
line (PBS) and were allowed to form cross-L structure over a period of
3 weeks at room temperature. Cross-L sheet formation was followed
by Congo red binding and examination of green birefringence under
polarized light.
2.5. Congo red staining
Freeze-dried bacterial endostatin was resuspended in either 0.1%
formic acid or in dimethylsulfoxide (DMSO) and taken up in a glass
capillary. The solvent was allowed to evaporate and the resulting
endostatin material was stained with Congo red (Sigma) according
to the manufacturer’s protocol.
2.6. Transmission electron microscopy (TEM)
Endostatin samples were applied to 400 mesh specimen grids cov-
ered with carbon-coated collodion ¢lms. After 5 min the drops were
removed with ¢lter paper and the preparations were stained with 1%
methylcellulose and 1% uranyl acetate. After washing in H2O the
samples were dehydrated in a graded series of EtOH and hexamethyl-
disilazane. Transmission electron micrographs were recorded at 60 kV
using a JEOL-1 electron microscope.
2.7. X-ray di¡raction analysis
Aggregated endostatin was solubilized in 0.1% FA and was taken
up in a glass capillary. The solvent was then allowed to evaporate
over a period of several days. Capillaries containing the dried samples
were placed on a Nonius UCCD di¡ractometer. Scattering was mea-
sured using sealed tube Mo KK radiation with a graphite monochro-
mator on the CCD area detector for a period of 16 h. Scattering from
air and the glass capillary wall were subtracted using in-house soft-
ware (VIEW/EVAL).
2.8. N1E-115 cell culture and di¡erentiation
N1E-115 mouse neuroblastoma cells were routinely cultured in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) containing 5% fetal calf
serum (FCS), supplemented with antibiotics. Cells were di¡erentiated
into post-mitotic neurons by culturing them in DMEM containing
0.5% FCS, 1 mM cAMP and 1% DMSO for 48 h.
2.9. Fluorescein isothiocyanate (FITC)-labeling and £uorescence
microscopy
Soluble (yeast-produced) endostatin was dialyzed against 0.01 M
Na2B4O7^0.15 M NaCl (pH 9.5) overnight. FITC was dissolved
(1 mg/ml) in 0.1 M Na2CO3 (pH 9.5) and was added to the endo-
statin, AL or hIAPP solutions at 2 Wg FITC/mg protein. After a 4 h
incubation at room temperature free FITC molecules were removed
by dialysis against 1 M Tris, pH 7.5, and subsequently, against PBS.
During this procedure endostatin stays soluble and becomes highly
£uorescent. Aggregated FITC-labeled endostatin was prepared from
soluble FITC-labeled endostatin as above. Freshly solubilized as well
as pre-aggregated AL and hIAPP were labeled with FITC by the same
protocol. Cells grown on glass coverslips were exposed to FITC-la-
beled soluble or aggregated endostatin (5 WM), freshly resuspended or
pre-aggregated AL or hIAPP for 6 h and were subsequently washed
¢ve times in PBS to discard unbound material. The coverslips were
then ¢xed by addition of formaldehyde (3.7% in PBS). Following
¢xation, the cells were incubated for 30 min in PBS^BSA (bovine
serum albumin; 0.1%) containing Texas red-conjugated phalloidin
to stain the actin cytoskeleton. The coverslips were then washed twice
with PBS and were subsequently mounted in Vectashield containing
DAPI (to stain cell nuclei) and analyzed using a Leica DM-IRBE
£uorescence microscope. Quantitation of aggregate binding to cells
was performed as follows: 10 random ¢elds were selected in a blind
manner (i.e. without knowledge of the coverslips’ identity) in the red
channel (actin). Images were subsequently automatically taken in all
three channels by using Q£uoro software. The images were then an-
alyzed by assessing the number of FITC-labeled aggregates per ¢eld
by using Leica Qwin software. Alternatively, the samples were ana-
lyzed by confocal microscopy (Leica) and images were processed using
Leica software.
2.10. Analysis of cell death
After exposure to endostatin or AL (25 WM, 24 h) cells in the cul-
ture medium were collected and the remaining adherent cells were
trypsinized and added to the detached cells in the medium, thus ob-
taining the total pool of adherent and detached cells. Subsequently,
the cells were stained with 0.02% Trypan blue and the percentage
dead (Trypan blue-positive) cells was assessed using a Bu«rker glass
counter chamber. Triplicate samples were analyzed and 200 cells were
counted in each sample.
2.11. Annexin V labeling
Cells were grown on glass coverslips and, following exposure to
either soluble or aggregated (non-£uorescent) endostatin or AL (25
WM, 24 h), were ¢xed in the culture medium using 3.7% formaldehyde.
Subsequently, the cells were analyzed for the presence of exposed
phosphatidyl-serine on the cell surface using FITC-labeled annexin
V (Sigma) according to the manufacturer’s protocol.
3. Results and discussion
3.1. Bacterial endostatin forms amyloid ¢bers with
cross-L structure
In solution, properly folded proteins or peptides form a
stable three-dimensional structure. However, protein frag-
ments (like endostatin) are often prone to (partial) denatura-
tion. As a result, they may aggregate and become insoluble.
Insoluble proteins may either exist as amorphous aggregates
or as highly ordered amyloid deposits [18]. The latter structure
results from extensive ‘cross-L sheet’ formation [19]. In cross-L
sheets the polypeptide backbones are in a L-sheet conforma-
tion with hydrogen bonds between the separate polypeptide
backbones. Congo red is a dye that is used for the detection of
cross-L sheet-forming amyloid deposits, showing green bire-
fringence under polarized light [20]. We found that insoluble
endostatin, as it is produced from bacteria, binds Congo red
(Fig. 1A). Furthermore, when examined under polarized light
it exhibits the green birefringence that is characteristic for
Congo red-bound amyloid deposits.
Next, we investigated whether cross-L sheets are indeed
present in bacterial endostatin by performing X-ray di¡rac-
tion analysis [21]. We found that the bacterial endostatin sam-
ple produced distinct re£ection lines at 4.7 AV (hydrogen-bond
distance), as well as at 10^11 AV (inter-sheet distance) (Fig.
1B). It is important to note that the re£ection lines at 4.7 AV
and 10^11 AV show maximal intensities at opposite di¡raction
angles (Fig. 1B). The ¢ber axis with its 4.7 AV hydrogen-bond
repeat distance is oriented along the vertical capillary axis.
This implies that the inter-sheet distance of 10^11 AV is per-
pendicular to these hydrogen bonds in the protein aggregates.
This is consistent with the protein being in a cross-L sheet
conformation (see also [22]). Intramolecular L-sheets in a
globular protein cannot cause a di¡raction pattern that is so
ordered. A rough estimate of 54 AV for the crystallite size in
the hydrogen-bond direction is obtained from the width of the
4.7 AV re£ection. This corresponds to about 11^12 L strands
connected by hydrogen bonds. The scattering of the 10^11 AV
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repeat is broad as usual. This is due both to the limited crys-
tallite size in the inter-sheet direction and to variation in the
inter-sheet distance. From the amount of background scatter-
ing it follows that only part of the protein is involved in cross-
L sheet formation.
Proteins and peptides that form cross-L sheets have the
tendency to aggregate into ¢brillar structures that can be vi-
sualized by TEM [23]. Therefore, we examined the endostatin
aggregates using TEM. Fig. 1C shows that bacterial endosta-
tin forms unbranched ¢bers with a diameter of approximately
300 AV (30 nm) and with lengths varying from 1500 to 5000 AV
(15^500 nm). Characteristic amyloid peptides form ¢brils with
diameters ranging from 50 to 130 AV (5^13 nm) [18] and with
varying lengths up to 1 Wm. Taken together, our results show
that bacterial endostatin is a protein fragment with an inher-
ent propensity to form cross-L sheets and to aggregate into
relatively thick amyloid-like ¢brils.
Fig. 1. Amyloid properties of endostatin produced in bacteria. A: Endostatin was puri¢ed from bacteria. The resulting aggregates were partially
dissolved in 0.1% formic acid, taken up in a glass capillary and were stained with Congo red. Samples were then analyzed by light microscopy
using both polarized and non-polarized light. The ¢gure shows that endostatin binds Congo red and exhibits green birefringence when exam-
ined under polarized light. B: Endostatin samples were prepared as in panel A and were subsequently analyzed by X-ray di¡raction. The scat-
tering as obtained on the 2D detector is color-coded by intensity on a linear scale. The scattering intensity decreases as white^yellow^red^blue^
black. The pattern shows di¡raction maxima at 4.7 and 10^11 AV . The ¢ber axis (hydrogen-bond direction) with 4.7 AV repeat is oriented verti-
cally and is indicated by the arrow. The 10^11 AV repeat is preferentially oriented perpendicular to that, as indicated by the asterisk. Tangential
scans along the 2a scattering angles corresponding to both d spacings in the lower panel show that the scattering at 4.7 AV is oriented vertically
and that at 10^11 AV horizontally. C: Endostatin samples were prepared as in A, but were coated on a 400 mesh grid and were processed for
TEM. Endostatin forms ¢brils with a diameter of V30 nm and lengths ranging from 150 to 500 nm. D: Model of the endostatin ¢ber. The
measured distances between individual peptide backbones (H-bonds) and between the distinct sheets are indicated, as well as the ¢ber axis (see
also [17]). A rough estimate of 54 AV for the crystallite size along the ¢ber axis corresponds to about 11^12 L strands connected by hydrogen
bonds.
6
Fig. 2. Conversion of soluble globular endostatin into amyloid en-
dostatin. Endostatin produced in yeast was dialyzed against 8 M
urea followed by extensive dialysis against H2O. During dialysis en-
dostatin precipitates as a ¢ne white solid. Formic acid (0.1%) was
added to both untreated and urea-treated endostatin preparations as
in Fig. 1A. The samples were subsequently processed for X-ray dif-
fraction analysis. A: Di¡raction pattern of untreated (yeast-pro-
duced) endostatin with no sign of cross-L sheet structure. B: Dif-
fraction pattern of urea-treated endostatin with extensive cross-L
sheet formation. During solvent evaporation ¢bril formation oc-
curred both vertically and horizontally in the capillary, as evidenced
by the occurrence of peaks at 90‡, 180‡, 270‡ and 0‡/360‡ in the
tangential scans corresponding to both d spacings. The asterisk indi-
cates the peak re£ection of the 10^11 AV d spacing at 90‡. The arrow
indicates the peak re£ection of the 4.7 AV d spacing at 180‡.
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3.2. Conversion of soluble yeast-produced endostatin into
amyloid endostatin
In contrast to bacterial endostatin, endostatin produced in
yeast is soluble, and neither binds Congo red, nor forms amy-
loid ¢brils when examined using TEM (data not shown). A
major di¡erence in the isolation protocols is a denaturation
step using 8 M urea during the isolation of endostatin from
bacteria, but not from yeast. Since amyloid formation occurs
via (partially) denatured intermediates [18], we considered the
possibility that this step may allow for the e⁄cient stacking of
endostatin monomers to form cross-L sheets. Therefore, we
subjected soluble yeast endostatin to the same denaturation/
renaturation protocol and examined the resulting preparation
for cross-L sheet content using X-ray di¡raction. Fig. 2A
shows that soluble endostatin produced in yeast does not
show any signs of cross-L sheet formation. The di¡raction
pattern is typical for any amorphous globular protein and
does not show a sharp re£ection line at 4.7 AV . Furthermore,
there is no perpendicular orientation of the di¡use re£ection
lines at 4.7 AV and 9^11 AV . The X-ray di¡raction data are in
line with our ¢ndings that soluble endostatin does not bind to
Congo red and does not form ¢brils. However, after denatur-
ation/renaturation we found extensive cross-L sheet formation
in yeast-produced endostatin (Fig. 2B). In addition to urea
treatment, protein denaturation through freeze^thawing or
heating also induced endostatin aggregation (data not shown).
We conclude that endostatin is a protein with a high propen-
sity to form amyloid aggregates, a process that is greatly
enhanced when the protein undergoes (partial) denaturation.
In this light it is interesting to note that the L-sheet content
measured in the endostatin crystal (25%) does not match the
percentage of L-sheet content of the original solution (70%)
[17,24]. This implies that the solution from which the crystal
has grown contained a L-sheet-rich form(s) of endostatin that
did not crystallize. Due to the intrinsic heterogeneity of cross-
L sheet forming proteins, crystallization of such structures is
notoriously di⁄cult.
3.3. Binding of endostatin to N1E-115 cells requires
cross-L structure
The prototype amyloid protein is AL, a 40^42 amino acid
peptide that is found as insoluble aggregates in neuronal tissue
and in the brain microvasculature of Alzheimer’s disease pa-
tients [25]. Like endostatin and many other amyloid proteins
or peptides, AL is a naturally occurring cleavage product of a
larger precursor protein [25]. In vitro, AL has toxic e¡ects on
both endothelial and neuronal cell types [26^31].
Based on the observed structural similarities between endo-
statin and AL we investigated whether endostatin would bind
to and be toxic to neuronal cells. To this end we used the
N1E-115 murine neuroblastoma cell line that can di¡erentiate
into post-mitotic neurons in vitro [32]. First, we tested
whether endostatin can bind to these cells. Soluble endostatin
was labeled with FITC and was either left untreated or was
treated to form amyloid aggregates as above. As controls we
also used FITC-labeled AL and hIAPP. The latter peptides
were used in two structural conformations: freshly resus-
pended (non-cross-L) and pre-aggregated (cross-L). Cells
Fig. 3. Binding of amyloid aggregates to N1E-115 neuroblastoma cells. A: Neuronal N1E-115 cells, grown on glass coverslips, were incubated
for 1 h with either FITC-labeled aggregated amyloid endostatin, soluble endostatin, AL freshly resuspended, AL pre-aggregated for 3 weeks
(AL amyloid), hIAPP freshly resuspended and hIAPP pre-aggregated for 3 weeks (hIAPP amyloid) (all at 5 WM). Cells were subsequently ex-
tensively washed and ¢xed. The actin cytoskeleton was stained using Texas red-conjugated palloidin (red) and the DNA with DAPI (blue). The
coverslips were then analyzed by conventional £uorescence microscopy. Shown are merged images. All amyloid aggregates (left panels) bound
N1E-115 cells. B: N1E-115 cells were pre-incubated for 6 h with non-£uorescent AL or hIAPP (at 5 WM) and the binding of FITC-labeled
amyloid endostatin (1 h, 5 WM) was subsequently tested as above. Digital image analysis shows that pre-incubation of the cells with AL and,
to a lesser extent, hIAPP diminishes endostatin binding (to 50% and 25%, respectively), suggesting that the aggregates have common cellular
binding sites. The bar diagram shows means of 10 randomly selected ¢elds in the red channel to avoid bias.
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were exposed to soluble or aggregated endostatin, to AL or to
hIAPP for 1 h. Following extensive washing and ¢xation,
binding of endostatin, AL and hIAPP to the cells was assessed
by £uorescence microscopy. Fig. 3A shows that soluble endo-
statin is found neither associated to the cells, nor inside the
cells, nor on the matrix surrounding the cells. In contrast, the
majority of amyloid endostatin is cell-associated. Some of the
deposits localized to the matrix, and some were found inside
the cells (see below). Like amyloid endostatin, both AL and
hIAPP readily bound to the cells. Two distinct types of ag-
gregates were observed: small endostatin-like aggregates as
well as larger aggregates that are not observed in the endo-
statin preparation. In the freshly resuspended (non-cross-L)
peptides the small aggregates were not observed but larger
aggregates were occasionally found to be cell-associated
(Fig. 3). It is well known that the formation of extensive
cross-L structure in these peptide aggregates may take days
to weeks.
When using high concentrations of soluble endostatin, we
observed occasional protein aggregation in the tissue culture
medium and these aggregates were found to bind to the cells
(Fig. 3 upper panel, arrow). This indicates once again the
propensity of soluble endostatin to undergo structural
changes leading to amyloid aggregation. Factors present in
the medium or in the serum may promote this conversion.
We reasoned that if cross-L structure underlies the binding
of aggregated endostatin to the cells, amyloid L and hIAPP
may compete for endostatin binding. We tested this by incu-
bating the cells for 6 h with either AL or with hIAPP prior to
incubation with amyloid endostatin for 1 h. The binding of
endostatin to the cells was then assessed by £uorescence mi-
croscopy and subsequent digital image analysis. Fig. 3B shows
that AL and, to a lesser extent, hIAPP compete with amyloid
endostatin for binding to the N1E-115 cells. Thus, amyloid
endostatin shares cellular binding sites with other amyloid
peptides, even though these peptides and endostatin do not
share any overt primary sequence homology. We next ex-
tended these observations by analyzing the binding of endo-
statin, AL and hIAPP to N1E-115 cells in more detail. To this
end we allowed binding of the FITC-labeled aggregates to the
cells as above and, following extensive washing and staining
of the actin acytoskeleton with Texas red phalloidin, the cell-
bound aggregates were examined by confocal microscopy.
Fig. 4 shows images of single cells and of highly zoomed
fragments of the cell surface in which discrete single aggre-
gates are visible. We found that the majority of all three
amyloid aggregates are in close proximity to the cortical ac-
tin-cytoskeleton that is connected to the plasma membrane
(Fig. 4). In addition, some of the aggregates are found inside
the cells (arrows), indicating that at least some internalization
of the aggregates can take place.
3.4. Amyloid but not soluble endostatin is cytotoxic to
N1E-115 neuroblastoma cells
Next, we analyzed whether the distinct forms of endostatin
would be cytotoxic to di¡erentiated N1E-115 cells and com-
pared their cytotoxicity with that induced by AL. Fig. 5A
shows that amyloid but not soluble endostatin binds to di¡er-
entiated N1E-115 cells as it does to the undi¡erentiated cells
(Figs. 3 and 4). Furthermore, we found that a 24 h exposure
of these cells to either AL or to amyloid endostatin induced
cell death, whereas soluble endostatin or bu¡er controls had
no e¡ect on neuronal cell viability (Fig. 5). Amyloid peptides
may induce either apoptosis or necrosis in neuronal and en-
dothelial cells. Annexin V strongly binds to exposed phospha-
tidyl-serine, a marker for apoptotic cell death. We found that
cells treated with amyloid endostatin, but not those treated
with soluble endostatin, are highly positive for £uorescent
annexin V (Fig. 5C), indicating that endostatin-induced cell
death is apoptotic in nature.
Interestingly, a recent report showed the production of en-
dostatin by neuronal cells and the localization of endostatin to
AL plaques in Alzheimer’s disease brain [33]. However, the
structural basis of this interaction was not examined. Given
our ¢nding that endostatin, like AL, has the propensity to
form cross-L structure, a cross-L type interaction may account
Fig. 4. Localization of cell-associated amyloid aggregates. N1E-115 cells were grown on glass coverslips and were incubated for 1 h with FITC-
labeled amyloid endostatin, AL and hIAPP. Actin was visualized using Texas red-conjugated phalloidin. The coverslips were analyzed by confo-
cal microscopy. Whole cell images (upper panel) show localization of all three amyloids mainly to the cell surface. In addition, some of the ag-
gregates show intracellular localization (arrows) (bar, 10 Wm). Zoomed images of cell surface areas (lower panel) show that all three types of
amyloid aggregates are in close proximity to the plasma membrane-bound cortical actin cytoskeleton (bar, 2 Wm).
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for their co-localization in vivo. Taken together, it seems
likely that endostatin may a¡ect neuronal cell function and
survival, also in vivo.
In addition to using neuronal N1E-115 cells we also used
bovine pulmonary aortic endothelial cells. We found that
amyloid endostatin, but not soluble endostatin, is highly cy-
totoxic to these cells as it is to the neuronal cells. In contrast,
neither soluble nor amyloid endostatin was cytotoxic to pri-
mary human umbilical vein endothelial cells nor to human
dermal microvascular endothelial cells (data not shown). At
present we do not know what determines the sensitivity of
(endothelial or neuronal) cells to amyloid endostatin. Possi-
bly, amyloid endostatin may exert its toxic e¡ects by activat-
ing amyloid receptors on the cell surface like receptor for
advanced glycation end products or scavenger receptors like
CD36 [34,35].
Can amyloid toxicity explain the anti-angiogenic e¡ect of
endostatin? We found the formation of liver metastases by
C26 murine colon cancer cells to be sensitive to treatment
with endostatin. In this model both soluble and amyloid endo-
statin inhibited tumor growth, but neither form caused tumor
regression [36] (and te Velde et al., submitted). Given the
propensity of soluble endostatin to aggregate and the inability
to control this phenomenon in vivo, it is impossible to assign
anti-tumor activity to a speci¢c structural form of endostatin.
4. Concluding remarks
Although many reports have shown e¡ects of either soluble
or insoluble endostatin on cell behavior [3], it is far from clear
which mechanisms underlie which phenomena. Induction of
apoptosis and inhibition of cell migration seem to be the most
commonly found cellular e¡ects [3]. Our results provide an
explanation for the observed cytotoxic e¡ects of endostatin.
Amyloid formation often occurs in protein fragments that are
taken out of their natural context (i.e. the full-length protein),
presumably due to partial denaturation [18]. The hydropho-
bicity of the peptide sequence and the propensity of the se-
quence to form L-sheets are critical determinants of protein
aggregation [37]. Recently it was found that two unrelated
protein fragments (which, unlike AL, are not related to any
disease) become highly toxic upon aggregation [38]. Taken
together, it seems likely that protein aggregation per se, inde-
pendent of the primary amino acid sequence, endows aggre-
gated amyloid proteins with an inherent toxicity [38]. The
results presented here suggest that endostatin can be added
to the list of ‘toxic-when-aggregated’ proteins. It is to be ex-
pected that this list will become much longer in the near
future. It is important to note that the extent of toxicity is
determined largely by the level of aggregation and the struc-
tural basis of aggregation [38]. These phenomena, in turn,
greatly depend on a number of parameters, including protein
production and storage protocols, pH, and choice of solvents.
Our results show that endostatin-induced cytotoxicity is re-
stricted to the aggregated amyloid form. Endostatin is toxic to
endothelial [7^9] and neuronal (this study) cells. These cell
types are also particularly sensitive to amyloid deposits [26^
31]. Our ¢nding that endostatin is a protein with amyloid
properties may therefore explain the cell-type speci¢city of
its cytotoxicity. If endostatin exerts its e¡ect through cellular
receptors, its bioactivity will depend on the expression of such
receptors on the target cells. Therefore, we are presently
studying whether endostatin can activate receptors that are
known to bind to cross-L sheet peptides.
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